BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22374424)

  • 21. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis.
    Shen XY; Lu FZ; Wu Y; Zhao LT; Lin ZF
    PLoS One; 2013; 8(8):e69553. PubMed ID: 23940523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
    Ren S; Zhou S; Wu F; Zhang L; Li X; Zhang J; Xu J; Lv M; Zhang J; Zhou C
    Lung Cancer; 2012 Jan; 75(1):102-9. PubMed ID: 21676483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
    Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
    Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.
    Kang S; Sun HY; Zhou RM; Wang N; Hu P; Li Y
    Asian Pac J Cancer Prev; 2013; 14(2):941-6. PubMed ID: 23621265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
    Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.
    Zhang L; Ma W; Li Y; Wu J; Shi GY
    Genet Mol Res; 2014 Jan; 13(1):228-36. PubMed ID: 24446315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy.
    Zhang ZY; Tian X; Wu R; Liang Y; Jin XY
    Asian Pac J Cancer Prev; 2012; 13(6):2583-6. PubMed ID: 22938424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
    Li XD; Han JC; Zhang YJ; Li HB; Wu XY
    Asian Pac J Cancer Prev; 2013; 14(1):145-8. PubMed ID: 23534713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
    Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
    Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Yang Y; Xian L
    Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
    Booton R; Ward T; Heighway J; Taylor P; Power F; Ashcroft L; Morris J; Thatcher N
    Cancer; 2006 Jun; 106(11):2421-7. PubMed ID: 16649224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
    Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
    Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
    Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
    Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
    J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
    Font A; Salazar R; Maurel J; Taron M; Ramirez JL; Tabernero J; Gallego R; Casado E; Manzano JL; Carcereny E; Guix M; Fernández-Llamazares J; Rosell R
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1075-83. PubMed ID: 18335219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Zhang XR; Xu BH; Lin DX
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):196-9. PubMed ID: 16875604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.